Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
1997

Enhanced oral bioavailability of paclitaxel in mice

Sample size: 6 publication Evidence: moderate

Author Information

Author(s): J van Asperen, O van Tellingen, A Sparreboom, AH Schinkel, P Borst, WJ Nooijen, JH Beijnen

Primary Institution: The Netherlands Cancer Institute

Hypothesis

Concomitant oral administration of a P-glycoprotein blocker might increase the absorption of orally administered paclitaxel from the intestinal lumen.

Conclusion

The oral bioavailability of paclitaxel is substantially increased by the concomitant administration of the P-glycoprotein blocker SDZ PSC 833.

Supporting Evidence

  • Paclitaxel's oral bioavailability increased from 20% to 210% with SDZ PSC 833.
  • The maximum plasma concentration of paclitaxel was fivefold higher with the blocker.
  • No significant toxicity was observed in treated mice over two months.

Takeaway

Giving mice a special blocker with paclitaxel helps them absorb the medicine better, making it more effective.

Methodology

Mice were treated with paclitaxel and SDZ PSC 833, and blood samples were collected to measure plasma concentration over time.

Limitations

The study was conducted in mice, which may not fully represent human responses.

Participant Demographics

Female FVB mice, 10-15 weeks of age.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication